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Human  biomonitoring  (HBM)  is  used  to indicate  and  quantify  exposure  by  measuring  environmental
chemicals,  their  metabolites  or reaction  products  in  biological  specimens.  The  biomonitoring  component
of  the Canadian  Health  Measures  Survey  (CHMS)  is the  most  comprehensive  initiative  providing  general
population  HBM  data  in  Canada.
The CHMS  is  an  ongoing  cross-sectional  direct  measures  survey  implemented  in  2-year  cycles.  It pro-
vides  nationally-representative  data  on  health,  nutritional  status,  environmental  exposures,  and  related
risks  and protective  characteristics.  The  survey  follows  a robust  planning,  design  and sampling  protocol
as well  as  a comprehensive  quality  assurance  and  quality  control  regime  implemented  for  all  aspect  of
the survey  to ensure  the  validity  of the  HBM  results.
HBM  blood  and  urine  data  are  available  for CHMS  cycles  1  (2007–2009),  2 (2009–2011)  and  3
(2012–2013).  Field  collection  has  been  completed  for cycle  4 (2014–2015),  with  cycle  5 (2016–2017)
in  progress  and  cycle  6 planning  (2018–2019)  being  ﬁnalized.  Biomonitoring  results  for  279  chemicals
are  expected  over  the  six cycles  of the CHMS  (220  in  individual  blood,  urine  or hair  samples,  and  59
in  pooled  serum  samples).  The  chemicals  include  metals  and  trace  elements,  polychlorinated  biphenyls
(PCBs),  organochlorines,  ﬂame  retardants,  perﬂuoroalkyl  substances,  volatile  organic  compounds  (VOCs)
and metabolites,  environmental  phenols,  triclocarban,  acrylamide,  pesticides  (e.g., triazines,  carbamates,
organophosphates,  phenoxy,  pyrethroids)  and/or  their  metabolites,  chlorophenols,  polycyclic  aromatic
hydrocarbon  (PAH)  metabolites,  phthalates  and  alternate  plasticizer  metabolites,  and  tobacco  biomark-
ers.  Approximately  one  half  of  the  chemicals  measured  in  individual  blood  and  urine  samples  over  the
ﬁrst  three  cycles  were  detected  in  more  than  60%  of samples.
CHMS  biomonitoring  data  have  been  used  to  establish  baseline  HBM  concentrations  in Canadians;
inform  public  health,  regulatory  risk  assessment  and  management  decisions;  and fulﬁl  national  and
international  reporting  requirements.  Concurrent  efforts  are  underway  in Canada  to  develop  statistically-
and  risk-based  concepts  and  tools  to interpret  biomonitoring  data.Crown  Copyright  © 2016  Published  by  Elsevier  GmbH.  All rights  reserved.
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. Introduction
Chemical substances are everywhere, in air, soil, water, food
nd products and can enter the body through ingestion, inhalation,
nd skin contact. Human biomonitoring (HBM) is used increasingly
o indicate and quantify exposure to environmental chemicals by
easuring the chemicals and/or their biotransformation products
n biological samples such as blood, urine, hair or milk (NRC, 2006;
exton et al., 2004). HBM is a rapidly advancing discipline used
or exposure and risk assessment in environmental and occupa-
ional health and contributes to the development of policies and
rograms to protect human health (Gurusankar et al., 2016; Haines
t al., 2012).
Prior to 2007, HBM studies in Canada were limited in scope and
ere carried out primarily on targeted populations such as those
n the Great Lakes and St. Lawrence basin (Tremblay and Gilman,
995; Human Health Component – St. Lawrence Vision 2000, 2003),
orthern populations (Donaldson et al., 2010), and Aboriginal peo-
les (Wheatley and Paradis, 1995). Although important information
nd knowledge were derived from these studies, they were not
opulation-representative and could not be used to characterize
he overall Canadian population.
In order to establish representative human biomonitoring data
or the Canadian general population, an extensive HBM compo-
ent has been incorporated into the Canadian Health Measures
urvey (CHMS) (Haines and Murray, 2012). The CHMS, which
as launched in 2007, is the most comprehensive direct health
easures survey conducted in Canada and is designed to pro-
ide nationally-representative data on indicators of environmental
xposures, health and nutritional status, and related risks and pro-
ective characteristics (Tremblay et al., 2007). The HBM component
f the CHMS assesses blood, urine and hair collected from survey
articipants for a wide range of environmental chemicals. CHMS
urveys have been completed and HBM data are available cur-
ently for cycle 1 (2007–2009), cycle 2 (2009–2011) and cycle 3
2012–2013).
The purpose of this paper is to describe the methods followed
or the HBM component of the ﬁrst three cycles of the CHMS sur-
ey, provide summary results for the chemicals measured in these
hree cycles, and highlight plans for future cycles and uses of CHMS
iomonitoring data.
. Methods
.1. Selection of environmental chemicals for CHMS
iomonitoring
The chemicals selected for the biomonitoring component of
he CHMS were based on a 2003 HBM expert workshop and
 2008 national consultation implemented through a question-Please cite this article in press as: Haines, D.A., et al., An overview of hu
Health Measures Survey: 2007–2019. Int. J. Hyg. Environ. Health (201
aire distributed to stakeholders across Canada. Participants in
hese consultations included Health Canada and other federal
overnment departments, provincial and territorial health and
nvironment departments, public health and medical laborato- . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . .  .  .  .  . .  .  .  .  .  . . . .  . . . . .  .  . .  .  .  .  . .  00
ries, the United States Centers for Disease Control and Prevention,
industry groups, non-governmental organizations, and academics.
In both these consultations, the following criteria were used as a
general guide for selecting the chemicals: seriousness of known
or suspected health effects related to the substance; current and
anticipated health policy development and implementations; level
of public concern about exposures and possible health effects;
evidence of exposure of the Canadian population to the sub-
stance and existing data gaps; feasibility of collecting biological
specimens in a national survey and associated burden on survey
participants; availability, efﬁciency and costs of laboratory ana-
lytical methods; parity of selected chemicals with other national
and international surveys; and commitments under national and
international treaties, conventions, and agreements. The chemical
groups selected for biomonitoring in CHMS cycles 1–6 (2007–2019)
are presented in Table 1 (the detailed list of chemicals, matrices and
age ranges measured in CHMS cycles 1–5 (2007–2017) and pro-
posed for cycle 6 (2018–2019) is provided in Supplemental Table
S1).
2.2. Target population
The CHMS cycles 1 and 2 targeted the population aged 6–79
years and 3–79 years, respectively, living at home and residing in
the 10 provinces and three territories of Canada. The CHMS cycle 3
targeted the population aged 3–79 years living at home and resid-
ing in the 10 provinces. Full-time members of Canadian Forces,
people living on Crown lands, First Nations reserves or in other
Aboriginal settlements in the provinces, residents of institutions
and certain remote regions, and persons living in areas with a low
population density were excluded from all three cycles of the sur-
vey. Notwithstanding these exclusions, the CHMS covers about 96%
of the general Canadian population (Giroux, 2007).
2.3. Sample size and allocation
In order to produce reliable estimates at the national level by
age group and sex, CHMS cycle 1 required a sample of at least 5000
persons equally distributed among ﬁve age groups (6–11, 12–19,
20–39, 40–59, 60–79 years) and sex for a total of 10 groups (Giroux,
2007). Cycles 2 and 3 each required a minimum sample of at least
5700 participants distributed among six age groups (3–5, 6–11,
12–19, 20–39, 40–59, and 60–79 years) and sex (except for 3–5
years), for a total of 11 groups (Statistics Canada, 2015, 2013). The
survey was not designed to provide estimates by sex for the 3–5
year age group.
2.4. Sampling strategy
2.4.1. Sampling of collection sitesman biomonitoring of environmental chemicals in the Canadian
6), http://dx.doi.org/10.1016/j.ijheh.2016.08.002
The CHMS used a stratiﬁed, multi-stage household-based sam-
pling strategy. For CHMS cycles 1 and 2, the Canadian Labour Force
Survey sampling frame (Statistics Canada, 2008) was used to cre-
ate 257 collection sites across the country. A geographic area with
ARTICLE IN PRESSG ModelIJHEH-12964; No. of Pages 16
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Table  1
Chemical groups selected for biomonitoring in cycles 1–6 (2007–2019) of the Canadian Health Measures Survey.
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
(2007–2009) (2009–2011) (2012–2013) (2014–2015) (2016–2017) (2018–2019)
Acrylamide – – X X X X
Alternate plasticizer metabolites – – – – X X
Carbamate pesticide metabolites – X – – – –
Chlorophenols X X – – – –
Dioxins and furans X – X X X X
Environmental phenols and triclocarban X X X X X X
Flame retardants X – X X X X
Fungicides and metabolites – – – – X X
Metals and trace elements X X X X X X
Organochlorines X – X X X X
Organophosphate insecticides and metabolites X X X X X X
Parabens – – X X X X
Perﬂuoroalkyl substances X X – – X X
Phenoxy herbicide X X – – – –
Phthalate metabolites X X – – X X
Polychlorinated biphenyls X – X X X X
Polycyclic aromatic hydrocarbon metabolites – X X X – –
Pyrethroid insecticide metabolites X X – – X X
Tobacco biomarkers X X X X X X
Triazine herbicide metabolites – X – – – –
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mVolatile organic compounds and metabolites – X 
 population of at least 10,000 and a maximum participant travel
istance of 100 km to a mobile examination centre (MEC) (50 km
n urban areas and 100 km in rural areas) were required for the
ocation of collection sites. For cycle 3, the 2011 Canadian Cen-
us geography was used to create 360 collection sites across the
ountry. A geographic area with a population of at least 10,000
nd a maximum participant travel distance of 75 km (50 km in
rban areas and 75 km in rural areas) were required for the loca-
ion of collection sites. Among the qualiﬁed sites, 15, 18 and 16
ollection sites were selected randomly for CHMS cycles 1, 2, and 3
espectively from within ﬁve standard regional boundaries used by
tatistics Canada (Atlantic, Quebec, Ontario, the Prairies, and British
olumbia). They were allocated to these regions in proportion to the
ize of the population. Although not every province and territory in
anada had a collection site in any cycle, the CHMS sites were cho-
en to represent the Canadian population, east to west, including
arger and smaller population densities.
.4.2. Dwelling and participant sampling
For CHMS cycles 1 and 2, the 2006 Canadian Census was  used
s the frame to select dwellings whereas the 2011 Canadian Cen-
us was used for cycle 3. Within each site, dwellings with known
ousehold composition at the time of the 2006 and 2011 Canadian
ensus, updated with the most recent information from adminis-
rative ﬁles, were stratiﬁed by age of household residents at the
ime of the survey, with the ﬁve age-group strata corresponding to
he cycle 1 age groups, and the six age-group strata corresponding
o the cycles 2 and 3 age groups. Within each site, a simple random
ample of dwellings was selected in each stratum. Each selected
welling was then contacted and asked to provide a list of current
ousehold members which was used for the ﬁnal selection of the
urvey participants.
.4.3. Sub-sampling
Many of the environmental chemicals were measured in sub-
amples of CHMS participants due to the costs of performing thesePlease cite this article in press as: Haines, D.A., et al., An overview of hu
Health Measures Survey: 2007–2019. Int. J. Hyg. Environ. Health (201
ests in the entire sample. Details on the sub-sampling for environ-
ental chemicals are available for CHMS cycles 1, 2 and 3 (Statistics
anada, 2015, 2013, 2010; Labrecque and Quigley, 2014). In sum-
ary, the sub-samples of respondents were selected randomly atX X X X
the dwelling (cycle 1) or MEC  (cycles 2 and 3) for blood and urine
measurements of environmental chemicals.
2.5. Ethical considerations
Information collected through the CHMS is protected under the
federal Statistics Act (Canada, 1970-71-72). The framework of poli-
cies, procedures, and practices and the steps taken to safeguard the
information collected in the CHMS have been described previously
(Day et al., 2007). Ethics approval for all components of the CHMS
was obtained from the Health Canada and Public Health Agency
of Canada Research Ethics Board. Informed written consent for the
MEC  portion of the CHMS was obtained from participants older than
14 years of age. For younger children, a parent or legal guardian pro-
vided written consent, and the child provided assent. Participation
in this survey was  voluntary, and participants could opt out of any
part of the survey at any time. A strategy was developed to commu-
nicate CHMS results to survey participants (Day et al., 2007; Haines
et al., 2011).
2.6. Fieldwork
Fieldwork for the CHMS cycles 1, 2, and 3 took place from
March 2007 to February 2009, August 2009 to November 2011, and
January 2012 to December 2013, respectively. Data were collected
sequentially at the selected sites across Canada which were ordered
to take into account seasonality by region and temporal effect. Steps
to recruit participants into both the household and MEC  portions
have been reported previously (Haines et al., 2011).
Data were collected from consenting survey participants
through a household personal interview and a visit to a MEC for
physical measures and biospecimen collection. Participants were
ﬁrst administered a household questionnaire in their home. Using
a computer application, the interviewer randomly selected one or
two participants and conducted separate health interviews which
collected demographic and socio-economic data and information
about lifestyle, medical history, current health status, the environ-man biomonitoring of environmental chemicals in the Canadian
6), http://dx.doi.org/10.1016/j.ijheh.2016.08.002
ment, and housing conditions (Statistics Canada, 2015, 2013, 2010).
Within approximately two  weeks after the home visit, participants
visited the MEC, which operated seven days a week in order to
accommodate participants’ schedules. The goal was to complete
 ING ModelI
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pproximately 350 visits at each site over 5–6 weeks. A parent or
egal guardian accompanied children under 14 years of age. To max-
mize response rates, participants who were unable or unwilling to
o to the MEC  were offered the option of a home visit by members of
he CHMS MEC  staff to perform some of the physical measures and
he biospecimen collection portion of the survey (Statistics Canada,
015).
Some tests (e.g. blood lipids, organochlorines) required that
he respondents fast. Approximately half of the respondents were
sked to fast prior to their MEC  appointment and were categorized
s “fasted” if they reported that they had fasted at least 10 h. 3 to 5
ear old children, pregnant women, people with diabetes and other
pecial cases were not asked to fast.
At the start of the MEC  visit, participants signed consent/assent
orms prior to any testing and in most cases, provided a urine sam-
le immediately thereafter. Spot samples were collected rather
han 24-h urine samples. Mid-stream urine samples were collected
n CHMS cycle 1 (Health Canada, 2010a) whereas ﬁrst-catch urine
amples were collected in cycles 2 and 3 (Health Canada, 2015,
013b). Beginning in cycle 2, participants were asked to abstain
rom urinating two hours prior to their MEC  visit. Blood specimens
ere drawn by a certiﬁed phlebotomist.
All blood and urine specimens collected in the MEC were pro-
essed and aliquoted in the MEC  according to standard operating
rocedures (summarized in Supplemental Table S2). Biospecimens
ere stored temporarily in temperature-monitored freezers at −20
o −30 ◦C until shipping, with the exception of blood samples col-
ected for volatile organic compound (VOC) analysis which were
efrigerated. Once a week, the specimens were shipped on dry ice
r in monitored refrigerated conditions to the laboratories for anal-
ses which were completed within eight weeks of receipt.
In CHMS Cycle 1, pooling of serum samples was performed based
n combining aliquots of surplus serum from individual partici-
ants to produce larger sample volumes for analysis of persistent
rganic pollutants by high resolution mass spectrometry. This was
ndertaken to reduce the number of undetected compounds and
llow national body burden estimates to be established for these
ubstances. The protocol for pooling of serum samples was  devel-
ped by Statistics Canada and has been described previously (Rawn
t al., 2014, 2012; Verret and Giroux, 2010).
To maximize the reliability and validity of the data and to reduce
ystematic bias, the CHMS established and implemented quality
ssurance and quality control protocols for all aspects of the ﬁeld-
ork. Quality assurance for the MEC  covered staff selection and
raining, instructions to respondents (pre-testing guidelines), and
ssues related to data collection. All staff had appropriate educa-
ion and training for their respective positions. To ensure consistent
easurement techniques, procedure manuals and training guides
ere developed and followed.
For the laboratory measures, where feasible, quality control
amples consisting of ﬁeld blanks, blind replicates, and blind qual-
ty control for each site were sent to the laboratory for analysis
ith regular specimen shipments. Results were sent to Statis-
ics Canada’s CHMS headquarters, along with all other respondent
esults, where they were assessed to determine the accuracy
f the methodology based on the deﬁned analyte concentra-
ion. The replicates were used to assess the overall precision
pre-analytic, analytic and post-analytic phases) of the analysis
ased on pre-established acceptable ranges. If required, feed-
ack was provided to the laboratory for review and remedial
ction. Blind commercial controls were not done for acrylamide,
nvironmental phenols (o-phenylphenol), metals (molybdenum,Please cite this article in press as: Haines, D.A., et al., An overview of hu
Health Measures Survey: 2007–2019. Int. J. Hyg. Environ. Health (201
ilver, tungsten, and uranium), perﬂuoroalkyl substances, phtha-
ates, triazine metabolites, 2,4-Dichlorophenoxyacetic acid (2,4-D),
obacco biomarkers (except for free cotinine), VOCs (styrene,
,1,1,2-tetrachloroethylene, and 1,1,2-trichloroethylene) because PRESS
nd Environmental Health xxx (2016) xxx–xxx
commercial controls were not readily available. In the case of
dioxins, furans, organochlorines, polychlorinated biphenyls, and
polybrominated ﬂame retardants, commercially available standard
reference materials were used to evaluate the precision and accu-
racy.
2.7. Laboratory analytical methods
Over the three cycles of the CHMS, laboratory analyses of
environmental chemicals and creatinine were performed at ana-
lytical laboratories within Health Canada, l’Institut national de
santé publique du Québec (INSPQ), and the ALS Laboratory Group.
Choice of the laboratory for the analysis of a given biomarker was
decided based on factors including its expertise in the analysis of
the biomarker in relevant biological matrices as well as its capac-
ity to process large number of samples consistently over an entire
CHMS cycle. Complete freedom was  provided to laboratories in
developing suitable new methods and/or adopting existing analyt-
ical methods for further development. In most cases, laboratories
developed analytical methods based on methods that were pub-
lished in peer-reviewed literature or implemented in large scale
biomonitoring studies. However, laboratories carried out speciﬁc
modiﬁcations to the procedures wherever necessary.
During the method validation phase, laboratories carried out
full validation studies to demonstrate the accuracy and preci-
sion of the analytical methods. The laboratories used a common
procedure to estimate method detection and quantiﬁcation lim-
its (US EPA, 2016). However, alternate procedures were used
by the laboratories when the baseline analyte concentrations
in the biological matrix were much higher than the expected
method detection limit. Laboratories used spike recovery studies
as well as the evaluation of matrix effects to assess the accu-
racy of the analytical methods. Where available, the accuracy
was also evaluated using standard reference materials/certiﬁed
reference materials (SRM/CRM). Precision studies included an ini-
tial evaluation of intra- and inter-day variation of the analytical
method during the routine analysis of the samples. Long-term
precision of the analytical method was  evaluated throughout the
cycle by analysing laboratory quality control samples. Techni-
cal personnel from Health Canada and Statistics Canada provided
advice to laboratories in troubleshooting issues throughout method
development and validation phases. The laboratories developed
standardized operating procedures for the analytical methods and
provided detailed method validation data. All method documen-
tations were reviewed internally at Health Canada and Statistics
Canada prior to their implementation in the CHMS. A condensed
version of the methods used in the analyses of the environmental
chemicals and creatinine have been described elsewhere (Health
Canada, 2015, 2013b, 2010a). For chemicals measured in blood
samples, metals and trace elements and volatile organic com-
pounds and metabolites were measured in whole blood, acrylamide
and glycidamide were measured as haemoglobin adducts, and
organochlorines, perﬂuoroalkyl substances and polychlorinated
biphenyls were measured in plasma.
As a part of regular sample analysis, the laboratories carried
out several quality control measures such as the analysis of cali-
bration standards, laboratory blanks, method blanks, and in-house
quality control samples in each analytical batch. In addition, lab-
oratories analysed a selected number of samples in duplicates
in each batch to establish repeatability of the analytical data.
Laboratory managers and/or quality specialist in each laboratory
conducted periodic quality assurance reviews to evaluate anyman biomonitoring of environmental chemicals in the Canadian
6), http://dx.doi.org/10.1016/j.ijheh.2016.08.002
issues in the batch processing and to identify inconsistencies in
analytical results.
As part of external quality control measures, laboratories partic-
ipated in external quality control programs such as inter-laboratory
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omparison studies and proﬁciency testing programs when avail-
ble. Some of the external quality assessment programs that the
aboratories participated in include External Quality Assessment
cheme (G-EQUAS), Germany, Lead and Multielement Proﬁciency
rogram (LAMP), USA, Interlaboratory Comparison Program for
etals in Biological Samples (PCI), and Arctic Monitoring and
ssessment Program (AMAP) ring test for persistent organic pol-
utants.
.8. Statistical analyses
Descriptive statistics on the concentrations of chemicals in the
lood and urine of Canadians were generated using SAS (SAS Insti-
ute Inc., 2011) and SUDAAN® (SUDAAN 2013) software. In order for
he results of the surveys to be representative of the entire popula-
ion, sample weights for each cycle of the CHMS were generated
y Statistics Canada and incorporated into all estimates. Survey
eights were used to take into account the unequal probability
f selection into the survey as well as non-response. Further, to
ccount for the complex survey design of the CHMS, bootstrap
eights established for each cycle were used to estimate the 95%
onﬁdence intervals (CI) for all means and percentiles (Rust and
ao, 1996; Rao et al., 1992). Biomarker concentrations that were
elow the LOD were assigned a value of LOD/2. The geometric
ean (GM) of a chemical was not calculated when the proportion of
esults below the LOD was greater than 40%. Estimates with coefﬁ-
ients of variation (CV) between 16.6% and 33.3% were considered
or general unrestricted release but accompanied with a caution
oting the high sampling variability associated with the estimate.
stimates with CV greater than 33.3% were not reported. Finally, all
escriptive statistics on the concentrations of chemicals in blood
nd urine were rounded to two signiﬁcant digits for consistency
cross CHMS cycles.
. Results
Of the persons selected at the household level to participate in
HMS, 74.9% (cycle 1), 73.9% (cycle 2) and 69.7% (cycle 3) reported
o the MEC  for the collection of physical measurements, including
lood and urine. A total of 176 chemicals were measured in individ-
al samples in the ﬁrst three cycles of the CHMS with 73 chemicals
easured in blood only, 90 measured in urine only and 13 mea-
ured in both blood and urine. An additional 52 chemicals (e.g.
CBs, ﬂame retardants, dioxins, furans, organochlorines) were mea-
ured exclusively in pooled serum samples over these ﬁrst three
urvey cycles. Measurements for 44 new chemicals in individual
amples and 7 new chemicals in pooled samples are planned for
HMS cycles 4, 5, and 6. These chemicals include 26 metals and
race elements planned for analysis in hair as part of cycles 5 and
. Therefore, over the ﬁrst six cycles of the CHMS (2007–2019), 220
hemicals will have been measured in individual samples and a
urther 59 chemicals in pooled samples, totalling 279 chemicals.
The concentrations of the environmental chemicals measured
n individual blood and urine samples in the ﬁrst three cycles of
he CHMS are presented in Tables 2 and 3 respectively. The tables
nclude the age group, survey years, sample size, LOD, percentage of
esults that fall below the LOD, GM,  25th, 50th, and 75th percentile
alues and their associated 95% CI. Results for acephate, malathion
icarboxylic acid, methamidophos, parabens, and 3,5,6-trichloro-
-pyridinol which were planned for measurement in cycle 3 werePlease cite this article in press as: Haines, D.A., et al., An overview of hu
Health Measures Survey: 2007–2019. Int. J. Hyg. Environ. Health (201
ending at the time of this publication. The proportion of any chem-
cal detected in individual blood or urine samples of Canadians
anged from zero to 100% in each of the three cycles. Over these
hree cycles, approximately one half of the chemicals measured in PRESS
nd Environmental Health xxx (2016) xxx–xxx 5
individual blood and urine samples were detected in more than 60%
of samples.
For metals and trace elements measured in whole blood over
the three survey cycles, low detection rates (i.e. >40% of samples
<LOD) were observed for silver and uranium and the GM concentra-
tions for the other chemicals were between 0.23 g/L for cobalt and
6400 g/L for zinc. In urine, low detection rates were observed for
all arsenic species (except dimethylarsinic acid), manganese (cycle
2), inorganic mercury, silver, tungsten, uranium, and vanadium. The
GM concentrations for the other metals and trace elements in urine
were between 0.042 g/L for antimony to 500 g/L for ﬂuoride.
Of the 14 biomarkers of organochlorines measured in plasma,
trans-nonachlor, oxychlordane, p,p′-DDE, hexachlorobenzene and
-hexachlorocyclohexane were detected in ≥60% of samples. Their
GM concentrations ranged from 0.025 g/L for oxychlordane to
0.91 g/L for p,p′-DDE. Of the 24 PCB congeners measured in indi-
vidual plasma samples of 20–79 year olds in CHMS cycle 1, 12
congeners were detected in ≥60% of samples. PCB 118, PCB 138, PCB
153 and PCB 180 were detected in over 90% of samples with GM
concentrations of 0.026, 0.060, 0.11 and 0.091 g/L respectively.
The only ﬂame retardant detected in ≥60% of plasma samples was
2,2′,4,4′-tetrabromodiphenyl ether (PBDE 47) with a GM concen-
tration of 0.065 g/L.
Three perﬂuoroalkyl substances were measured in CHMS cycle
1 and nine in cycle 2. Perﬂuorobutanoic acid (PFBA), perﬂuoro-
hexanoic acid (PFHxA) and perﬂuorobutane sulfonate (PFBS) were
detected in fewer than 2% of samples. Over the two survey cycles,
the GM concentrations of the other perﬂuoroalkyl substances
ranged from 0.12 g/L for perﬂuoroundecanoic acid (PFUnDA) to
8.9 g/L for perﬂuorooctane sulfonate (PFOS).
Acrylamide (HbAA) and glycidamide (HbGA) haemoglobin
adducts measurements were done in individual blood samples col-
lected from 3 to 79 year olds in CHMS cycle 3 (2012–2013). HbAA
was detected in 100% and HbGA in 99.2% of samples with GM con-
centrations of 73 pmol/g Hb and 68 pmol/g Hb respectively.
Twelve VOC biomarkers were measured in whole blood of 12–79
year olds in CHMS cycle 3. The biomarkers which were detected in
≥60% of samples had detection rates and GMs  as follows: benzene
87.4%, 0.036 g/L; ethylbenzene 82.1%, 0.026 g/L, styrene 92.4%,
0.043 g/L; toluene 99.3%, 0.096 g/L; and m-  and p-xylene 85.5%,
0.062 g/L. The GM concentrations for the three benzene metabo-
lites measured in urine from 3–79 year olds in CHMS cycles 2
and 3 were 0.17–0.20 g/L for S-phenylmercapturic acid (S-PMA),
56–64 g/L for trans,trans-muconic acid (t,t-MA), and 6600 g/L
for phenol.
Of the environmental phenols measured in urine, bisphenol A
(BPA) was  detected in more than 90% of samples with GM con-
centrations between 1.1 and 1.2 g/L over the three cycles of the
CHMS. The urinary triclosan GM concentrations for 3–79 year olds
were 16 and 17 g/L in CHMS cycles 2 and 3, respectively. Parabens
were measured in CHMS cycle 3 but data were not available at the
time of this paper. Triclocarban was  detected in fewer than 4% of
samples.
Ten organophosphate insecticides and metabolites have been
included for urine measurement over the three survey cycles.
Results are currently available for six dialkyl phosphate metabo-
lites collected from 6–79 year olds and 3–79 year olds in the
ﬁrst two survey cycles. Of these, dimethylphosphate (DMP),
dimethylthiophosphate (DMTP), diethylphosphate (DEP) and
diethylthiophosphate (DETP) had frequencies of detection of ≥60%
and their GM concentrations ranged from 0.66 g/L for DETP
to 3.3 g/L for DMP. Triazine and carbamate pesticide metabo-man biomonitoring of environmental chemicals in the Canadian
6), http://dx.doi.org/10.1016/j.ijheh.2016.08.002
lites measured in urine of 3–79 year olds in CHMS cycle 2 were
below LOD in more than 99% of samples. Four (cis-DBCA, cis-DCCA,
trans-DCCA, 3-PBA) of the ﬁve pyrethroid insecticide metabolites
measured in urine in CHMS cycles 1 and 2 were detected in ≥60% of
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Table 2
Concentrationsa of environmental chemicals measured in individual blood samples of the Canadian population, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011) and cycle 3 (2012–2013).
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
Acrylamide (haemoglobin adducts)
Acrylamide haemoglobin adduct 3–79 2012–2013 2492 10 0 73 (65–82) 47 (42–52) 64 (57–70) 100 (82–120)
Glycidamide haemoglobin adduct 3–79 2012–2013 2492 20 0.76 68 (62–75) 47 (44–50) 65 (59–70) 95 (86–100)
Flame  retardants (plasma)
2,2′ ,4,4′ ,5,5′-Hexabromobiphenyl (PBB 153) 20–79 2007–2009 1657 0.02 96.56 – <LOD <LOD <LOD
4,4′-Dibromodiphenyl ether (PBDE 15) 20–79 2007–2009 1663 0.03 99.82 – <LOD <LOD <LOD
2,2′ ,4-Tribromodiphenyl ether (PBDE 17) 20–79 2007–2009 1663 0.03 100 – <LOD <LOD <LOD
2,3′ ,4-Tribromodiphenyl ether (PBDE 25) 20–79 2007–2009 1663 0.03 100 – <LOD <LOD <LOD
2,4,4′-Tribromodiphenyl ether (PBDE 28) 20–79 2007–2009 1663 0.03 96.75 – <LOD <LOD <LOD
2′ ,3,4-Tribromodiphenyl ether (PBDE 33) 20–79 2007–2009 1663 0.03 100 – <LOD <LOD <LOD
2,2′ ,4,4′-Tetrabromodiphenyl ether (PBDE 47) 20–79 2007–2009 1668 0.03 25.24 0.065 (0.059–0.071) <LOD 0.058 (0.050–0.066) 0.12 (0.10–0.14)
2,2′ ,4,4′ ,5-Pentabromodiphenyl ether (PBDE 99) 20–79 2007–2009 1665 0.02 73.21 – <LOD <LOD 0.021 (<LOD–0.026)
2,2′ ,4,4′ ,6-Pentabromodiphenyl ether (PBDE 100) 20–79 2007–2009 1664 0.02 73.98 – <LOD <LOD 0.021 (<LOD–0.027)
2,2′ ,4,4′ ,5,5′-Hexabromodiphenyl ether (PBDE 153) 20–79 2007–2009 1659 0.02 58.65 – <LOD <LOD 0.033 (0.027–0.039)
Metals  and trace elements (whole blood)
Arsenic (total) 6–79 2007–2009 5319 0.23 7.24 0.88 (0.73–1.1) 0.49 (0.37–0.60) 0.86 (0.72–1.0) 1.4 (1.2–1.7)
Cadmium  6–79 2007–2009 5319 0.04 2.91 0.34 (0.31–0.37) 0.14d (0.067–0.22) 0.27 (0.25–0.29) 0.62 (0.55–0.70)
3–79  2009–2011 6070 0.04 5.16 0.29 (0.26–0.32) 0.097 (0.095–0.099) 0.26 (0.24–0.29) 0.54 (0.49–0.59)
3–79  2012–2013 5538 0.08 11.48 0.33 (0.30–0.36) 0.12d (<LOD–0.17) 0.27 (0.25–0.29) 0.58 (0.47–0.68)
Cobalt  3–79 2009–2011 6070 0.04 0.02 0.23 (0.21–0.24) 0.18 (0.16–0.19) 0.22 (0.20–0.23) 0.27 (0.25–0.29)
Copper  6–79 2007–2009 5318 0.6 0 910 (900–930) 810 (790–820) 880 (870–900) 990 (980–1000)
3–79  2009–2011 6070 20 0 900 (890–910) 770 (760–780) 860 (850–860) 950 (940–960)
Lead  6–79 2007–2009 5319 0.2 0.02 13 (12–14) 8.6 (7.9–9.3) 12 (12–13) 20 (18–22)
3–79  2009–2011 6070 1.0 0 12 (11–12) 7.7 (7.2–8.2) 11 (11–12) 17 (16–18)
3–79  2012–2013 5538 2.0 0.09 11 (10–11) 6.7 (6.2–7.2) 10 (9.5–11) 16 (16–17)
Manganese 6–79 2007–2009 5309 0.05 0 9.2 (9.0–9.5) 7.5 (7.3–7.6) 9.0 (8.8–9.3) 11 (10–11)
3–79  2009–2011 6070 0.5 0 9.8 (9.5–10) 7.8 (7.6–8.0) 9.5 (9.1–9.8) 12 (11–12)
Mercury  (total) 6–79 2007–2009 5319 0.1 11.64 0.69 (0.55–0.86) 0.28 (0.21–0.35) 0.81 (0.64–0.97) 1.6 (1.1–2.0)
3–79  2009–2011 6070 0.1 15.55 0.69 (0.56–0.87) 0.22d (0.12–0.32) 0.74 (0.55–0.93) 1.7 (1.2–2.1)
3–79  2012–2013 5538 0.4 37.02 0.79 (0.64–0.97) <LOD 0.79 (0.62–0.96) 1.5 (1.1–2.0)
Methylmercury 20–79 2012–2013 1032 0.2 18.70 0.64 (0.48–0.84) 0.23 (<LOD–0.30) 0.72 (0.50–0.95) 1.5 (0.98–2.0)
Molybdenum 6–79 2007–2009 5319 0.1 0.09 0.67 (0.65–0.69) 0.51 (0.49–0.52) 0.66 (0.64–0.67) 0.85 (0.82–0.89)
3–79  2009–2011 6070 0.1 0.16 0.66 (0.64–0.68) 0.49 (0.47–0.50) 0.64 (0.62–0.66) 0.86 (0.83–0.88)
Nickel  6–79 2007–2009 5319 0.4 6.69 0.63 (0.57–0.70) 0.44 (0.40–0.47) 0.53 (0.52–0.55) 0.60d (<LOD–1.0)
3–79  2009–2011 6067 0.3 11.95 0.45 (0.42–0.49) 0.36 (0.33–0.38) 0.47 (0.44–0.49) 0.55 (0.54–0.56)
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Table 2 (Continued)
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
Selenium 6–79 2007–2009 5319 8.0 0 200 (200–210) 180 (170–180) 200 (190–200) 220 (210–220)
3–79  2009–2011 6070 20 0 190 (190–190) 170 (160–170) 180 (180–190) 200 (200–210)
Silver  3–79 2009–2011 6070 0.05 45.78 – <LOD 0.062d (<LOD–0.091) 0.096 (0.093–0.099)
Uranium 6–79 2007–2009 5304 0.005 93.02 – <LOD <LOD <LOD
3–79  2009–2011 6070 0.007 98.80 – <LOD <LOD <LOD
Zinc  6–79 2007–2009 5319 0.7 0 6400 (6300–6500) 5700 (5700–5800) 6400 (6300–6400) 7000 (6900–7100)
3–79  2009–2011 6070 100 0 5900 (5900–6000) 5400 (5300–5400) 6000 (5900–6000) 6400 (6400–6500)
Organochlorines (plasma)
Aldrin 20–79 2007–2009 1666 0.010 100 – <LOD <LOD <LOD
Chlordane
-Chlordane 20–79 2007–2009 1666 0.010 100 – <LOD <LOD <LOD
-Chlordane 20–79 2007–2009 1666 0.005 99.70 – <LOD <LOD <LOD
cis-Nonachlor 20–79 2007–2009 1668 0.005 49.04 – <LOD <LOD 0.0078 (0.0067–0.0090)
trans-Nonachlor 20–79 2007–2009 1668 0.010 6.00 0.036 (0.032–0.040) 0.020 (0.019–0.021) 0.038 (0.033–0.042) 0.067 (0.058–0.075)
Oxychlordane 20–79 2007–2009 1668 0.005 2.58 0.025 (0.023–0.028) NRe 0.027 (0.025–0.029) 0.045 (0.041–0.049)
Dichlorodiphenyltrichloroethane (DDT)
p,p′-Dichlorodiphenyltrichloroethane (p,p′-DDT) 20–79 2007–2009 1666 0.050 90.64 – <LOD <LOD <LOD
p,p′-Dichlorodiphenyldichloroethylene (p,p′-DDE) 20–79 2007–2009 1668 0.090 0.36 0.91 (0.76–1.1) 0.42 (0.37–0.46) 0.75 (0.59–0.91) 1.7 (1.3–2.1)
Hexachlorobenzene 20–79 2007–2009 1668 0.040 24.70 0.054 (0.048–0.061) <LOD 0.053 (0.048–0.058) 0.080 (0.069–0.092)
Hexachlorocyclohexane
-Hexachlorocyclohexane 20–79 2007–2009 1668 0.010 6.95 0.038 (0.028–0.052) 0.017 (0.015–0.018) 0.031 (0.025–0.037) 0.063 (0.042–0.084)
-Hexachlorocyclohexane (Lindane) 20–79 2007–2009 1665 0.010 99.34 – <LOD <LOD <LOD
Mirex  20–79 2007–2009 1668 0.010 47.36 – <LOD <LOD 0.015 (0.011–0.019)
Toxaphene
Toxaphene Parlar 26 20–79 2007–2009 1666 0.005 73.71 – <LOD <LOD <LOD
Toxaphene Parlar 50 20–79 2007–2009 1667 0.005 52.31 – <LOD <LOD 0.0069 (0.0055–0.0084)
Perﬂuoroalkyl substances (plasma)
Perﬂuorobutanoic acid (PFBA) 12–79 2009–2011 1524 0.5 99.67 – <LOD <LOD <LOD
Perﬂuorohexanoic acid (PFHxA) 12–79 2009–2011 1524 0.1 98.10 – <LOD <LOD <LOD
Perﬂuorooctanoic acid (PFOA) 20–79 2007–2009 2880 0.3 1.11 2.5 (2.4–2.7) 1.9 (1.7–2.0) 2.6 (2.4–2.8) 3.6 (3.4–3.8)
12–79  2009–2011 1524 0.1 0 2.3 (2.1–2.5) 1.6 (1.3–1.8) 2.3 (2.1–2.5) 3.2 (2.8–3.6)
Perﬂuorononanoic acid (PFNA) 12–79 2009–2011 1524 0.2 1.05 0.82 (0.75–0.90) 0.55 (0.44–0.66) 0.80 (0.70–0.90) 1.1 (0.96–1.2)
Perﬂuorodecanoic acid (PFDA) 12–79 2009–2011 1524 0.1 21.59 0.20 (0.17–0.22) 0.11 (<LOD–0.13) 0.17 (0.15–0.19) 0.27 (0.23–0.30)
Perﬂuoroundecanoic acid (PFUnDA) 12–79 2009–2011 1522 0.09 39.29 0.12 (0.098–0.14) <LOD 0.095 (LOD–0.10) 0.18 (0.14–0.22)
Perﬂuorobutane sulfonate (PFBS) 12–79 2009–2011 1524 0.4 100 – <LOD <LOD <LOD
Perﬂuorohexane sulfonate (PFHxS) 20–79 2007–2009 2880 0.3 2.05 2.3 (2.0–2.6) 1.2 (1.0–1.4) 2.2 (1.8–2.5) 3.7 (3.2–4.1)
12–79  2009–2011 1521 0.2 1.25 1.8 (1.6–2.0) 0.99 (0.92–1.1) 1.7 (1.5–1.9) 2.8 (2.2–3.5)
Perﬂuorooctane sulfonate (PFOS) 20–79 2007–2009 2880 0.3 0.14 8.9 (8.0–9.8) 5.7 (5.0–6.4) 9.1 (8.1–10) 13 (12–15)
12–79  2009–2011 1524 0.3 0.33 6.5 (6.0–7.2) 4.4 (3.9–5.0) 6.7 (6.1–7.3) 10 (9.3–11)
Polychlorinated biphenyls (plasma)
2,4,4′-Trichlorobiphenyl (PCB 28) 20–79 2007–2009 1661 0.05 98.62 – <LOD <LOD <LOD
2,2′ ,5,5′-Tetrachlorobiphenyl (PCB 52) 20–79 2007–2009 1661 0.30 100 – <LOD <LOD <LOD
2,3′ ,4,4′-Tetrachlorobiphenyl (PCB 66) 20–79 2007–2009 1666 0.03 98.20 – <LOD <LOD <LOD
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Table 2 (Continued)
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
2,4,4′ ,5-Tetrachlorobiphenyl (PCB 74) 20–79 2007–2009 1668 0.03 53.06 – <LOD <LOD 0.040 (0.034–0.046)
2,2′ ,4,4′ ,5-Pentachlorobiphenyl (PCB 99) 20–79 2007–2009 1668 0.03 70.56 – <LOD <LOD <LOD
2,2′ ,4,5,5′-Pentachlorobiphenyl (PCB 101) 20–79 2007–2009 1666 0.03 99.40 – <LOD <LOD <LOD
2,3,3′ ,4,4′-Pentachlorobiphenyl (PCB 105) 20–79 2007–2009 1668 0.01 71.10 – <LOD <LOD <LOD
2,3′ ,4,4′ ,5-Pentachlorobiphenyl (PCB 118) 20–79 2007–2009 1668 0.01 9.65 0.026 (0.022–0.031) NRe 0.025 (0.021–0.029) 0.050 (0.041–0.058)
2,2′ ,3,3′ ,4,4′-Hexachlorobiphenyl (PCB 128) 20–79 2007–2009 1666 0.01 98.74 – <LOD <LOD <LOD
2,2′ ,3,4,4′ ,5′-Hexachlorobiphenyl (PCB 138) 20–79 2007–2009 1668 0.01 1.44 0.060 (0.053–0.069) 0.031 (0.026–0.036) 0.060 (0.051–0.068) 0.11 (0.97–0.13)
2,2′ ,3,4′ ,5,5′-Hexachlorobiphenyl (PCB 146) 20–79 2007–2009 1668 0.01 37.11 0.012 (0.010–0.013) <LOD <LOD 0.022 (0.019–0.024)
2,2′ ,4,4′ ,5,5′-Hexachlorobiphenyl (PCB 153) 20–79 2007–2009 1668 0.01 2.52 0.11 (0.095–0.13) 0.056 (0.047–0.064) 0.12 (0.10–0.13) 0.21 (0.18–0.24)
2,3,3′ ,4,4′ ,5-Hexachlorobiphenyl (PCB 156) 20–79 2007–2009 1668 0.01 28.78 0.016 (0.014–0.017) <LOD 0.018 (0.016–0.020) 0.032 (0.029–0.036)
2,3,3′ ,4′ ,5,6-Hexachlorobiphenyl (PCB 163) 20–79 2007–2009 1668 0.01 21.34 0.019 (0.017–0.022) <LOD 0.020 (0.018–0.023) 0.038 (0.033–0.043)
2,3′ ,4,4′ ,5,5′-Hexachlorobiphenyl (PCB 167) 20–79 2007–2009 1668 0.01 75.48 – <LOD <LOD <LOD
2,2′ ,3,3′ ,4,4′ ,5-Heptachlorobiphenyl (PCB 170) 20–79 2007–2009 1668 0.01 14.87 0.027 (0.025–0.031) <LOD (<LOD–0.011) 0.031 (0.027–0.034) 0.059 (0.052–0.065)
2,2′ ,3,3′ ,5,5′ ,6-Heptachlorobiphenyl (PCB 178) 20–79 2007–2009 1668 0.01 61.57 – <LOD <LOD <LOD
2,2′ ,3,4,4′ ,5,5′-Heptachlorobiphenyl (PCB 180) 20–79 2007–2009 1668 0.01 1.38 0.091 (0.082–0.10) 0.042 (0.035–0.050) 0.099 (0.093–0.11) 0.19 (0.17–0.22)
2,2′ ,3,4,4′ ,5′ ,6-Heptachlorobiphenyl (PCB 183) 20–79 2007–2009 1668 0.01 48.92 – <LOD <LOD 0.019 (0.015–0.022)
2,2′ ,3,4′ ,5,5′ ,6-Heptachlorobiphenyl (PCB 187) 20–79 2007–2009 1668 0.01 19.60 0.022 (0.019–0.025) <LOD 0.024 (0.019–0.028) 0.044 (0.038–0.051)
2,2′ ,3,3′ ,4,4′ ,5,5′-Octachlorobiphenyl (PCB 194) 20–79 2007–2009 1668 0.01 29.50 0.017 (0.016–0.019) <LOD 0.020 (0.019–0.020) 0.040 (0.033–0.046)
2,2′ ,3,3′ ,4,5′ ,6,6′-Octachlorobiphenyl (PCB 201) 20–79 2007–2009 1668 0.01 30.88 0.015 (0.014–0.017) <LOD 0.017d (<LOD–0.025) 0.032 (0.027–0.037)
2,2′ ,3,4,4′ ,5,5′ ,6-Octachlorobiphenyl (PCB 203) 20–79 2007–2009 1668 0.01 35.61 0.013 (0.012–0.014) <LOD <LOD (<LOD–0.011) 0.027 (0.024–0.031)
2,2′ ,3,3′ ,4,4′ ,5,5′ ,6-Nonachlorobiphenyl (PCB 206) 20–79 2007–2009 1668 0.01 56.89 – <LOD <LOD <LODd (<LOD–0.016)
Volatile  organic compounds and metabolites (whole blood)
Benzene 12–79 2012–2013 2488 0.007 12.58 0.036 (0.025–0.050) 0.20d (0.0087–0.031) 0.039 (0.030–0.049) 0.067 (0.051–0.083)
Ethylbenzene 12–79 2012–2013 2441 0.010 17.90 0.026 (0.020–0.033) 0.014 (<LOD–0.019) 0.025 (0.017–0.033) 0.052 (0.040–0.063)
Styrene  12–79 2012–2013 2063 0.010 7.61 0.043d (0.029–0.062) 0.028d (0.016–0.039) 0.043 (0.030–0.055) 0.070d (0.044–0.096)
Tetrachloroethylene (perchloroethylene) 12–79 2012–2013 2453 0.020 60.82 – <LOD <LOD 0.044 (0.031–0.057)
Toluene  12–79 2012–2013 2449 0.010 0.69 0.096 (0.083–0.11) 0.049 (0.041–0.058) 0.079 (0.067–0.090) 0.16 (0.13–0.19)
Trichloroethylene 12–79 2012–2013 2474 0.030 99.51 – <LOD <LOD <LOD
Trihalomethanes
Bromodichloromethane 12–79 2012–2013 2499 0.010 99.88 – <LOD <LOD <LOD
Dibromochloromethane 12–79 2012–2013 2527 0.007 97.07 – <LOD <LOD <LOD
Tribromomethane (bromoform) 12–79 2012–2013 2496 0.010 94.79 – <LOD <LOD <LOD
Trichloromethane (chloroform) 12–79 2012–2013 2527 0.010 77.44 – <LOD <LOD <LOD
Xylenes
m-Xylene & p-xylene 12–79 2012–2013 2326 0.020 14.53 0.062 (0.050–0.079) 0.036 (0.026–0.046) 0.063 (0.047–0.080) 0.11 (0.089–0.14)
o-Xylene 12–79 2012–2013 2336 0.009 41.05 – <LOD 0.022d (0.010–0.034) 0.045 (0.030–0.060)
CI: conﬁdence interval; GM:  geometric mean; LOD: limit of detection; NR: not reported; P25: 25th percentile; P50: 50th percentile; P75: 75th percentile.
a Units for all chemicals are in g/L except for acrylamide and glycidamide haemoglobin (Hb) adducts which are expressed as pmol/g Hb, and methylmercury as g mercury (Hg)/L.
b Sample sizes are the actual unweighted number of participants. GMs, percentiles and CIs are weighted estimates.
c GM was not calculated when the percentage of results <LOD was  greater than 40%.
d Coefﬁcient of variation is between 16.6% and 33.3%, use data with caution.
e Coefﬁcient of variation is greater than 33.3%, data are not reported.
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Table 3
Concentrationsa of environmental chemicals measured in individual urine samples of the Canadian population, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011) and cycle 3 (2012–2013).
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
Carbamate pesticide metabolites
Carbofuranphenol 3–79 2009–2011 2557 0.1 99.96 – <LOD <LOD <LOD
2-Isopropoxyphenol 3–79 2009–2011 2560 0.05 99.80 – <LOD <LOD <LOD
Chlorophenols
2,4-Dichlorophenol (2,4-DCP) 6–79 2007–2009 5479 0.3 21.81 0.94 (0.83–1.1) 0.32 (<LOD–0.40) 0.83 (0.68–0.97) 2.2 (1.8–2.6)
3–79  2009–2011 2545 0.3 12.14 1.2 (0.98–1.4) 0.48 (0.39–0.57) 1.0 (0.86–1.1) 2.3 (1.7–2.9)
2,5-Dichlorophenol (2,5-DCP) 3–79 2009–2011 2544 0.3 4.05 5.5 (4.5–6.9) 1.7 (1.3–2.2) 5.0 (3.7–6.2) 15 (12–19)
2,4,5-Trichlorophenol (2,4,5-TCP) 3–79 2009–2011 2560 0.5 97.46 – <LOD <LOD <LOD
2,4,6-Trichlorophenol (2,4,6-TCP) 3–79 2009–2011 2559 1 93.98 – <LOD <LOD <LOD
Pentachlorophenol (PCP) 3–79 2009–2011 2551 0.7 96.55 – <LOD <LOD <LOD
Environmental phenols and triclocarban
Bisphenol A 6–79 2007–2009 5476 0.2 9.26 1.2 (1.1–1.2) 0.54 (0.47–0.61) 1.3 (1.1–1.4) 2.5 (2.2–2.8)
3–79  2009–2011 2560 0.2 5.04 1.2 (1.1–1.3) 0.62 (0.55–0.68) 1.2 (1.1–1.3) 2.4 (2.1–2.6)
3–79  2012–2013 5670 0.2 7.80 1.1 (1.0–1.2) 0.59 (0.46–0.72) 1.1 (0.95–1.2) 2.2 (1.9–2.4)
Triclocarban 3–79 2009–2011 2549 1 96.23 – <LOD <LOD <LOD
Triclosan  3–79 2009–2011 2550 3 28.20 16 (13–20) <LOD 9.5f (5.8–13) NRg
3–79 2012–2013 5645 5 34.47 17 (15–19) <LOD 9.9 (8.4–11) 67 (48–86)
Metals  and trace elements
Antimony 6–79 2007–2009 5492 0.02 22.40 0.042 (0.040–0.045) 0.020f (<LOD–0.028) 0.043 (0.040–0.045) 0.079 (0.074–0.083)
3–79  2009–2011 6311 0.02 20.00 0.046 (0.044–0.048) 0.020 (<LOD–0.024) 0.046 (0.043–0.048) 0.086 (0.081–0.091)
Arsenic  (total) 6–79 2007–2009 5492 0.5 0.18 12 (9.9–14) 5.8 (5.0–6.6) 11 (8.8–13) 23 (18–28)
3–79  2009–2011 6311 0.7 1.96 8.9 (7.5–11) 4.2 (3.5–4.8) 7.8 (6.7–8.9) 19 (15–24)
Arsenic  (speciated)
Arsenate (arsenic [V] acid) 3–79 2009–2011 2538 0.8 99.49 – <LOD <LOD <LOD
3–79  2012–2013 2536 0.8 99.25 – <LOD <LOD <LOD
Arsenite  (arsenous [III] acid) 3–79 2009–2011 2537 0.8 75.60 – <LOD <LOD 0.72f (<LOD–1.0)
3–79  2012–2013 2535 0.8 73.96 – <LOD <LOD NRg
Arsenocholine 3–79 2012–2013 2536 0.8 100 – <LOD <LOD <LOD
0.8
Arsenocholine and arsenobetaine 3–79 2009–2011 2538 0.8 48.50 – <LOD 1.4f (<LOD–2.2) 6.7f (3.7–9.7)
3–79 2012–2013 2536 0.8 48.15 – <LOD 1.4f (<LOD–2.1) 7.0 (4.7–9.3)
Dimethylarsinic acid (DMA) 3–79 2009–2011 2538 0.8 3.78 3.5 (3.0–4.0) 1.9 (1.7–2.2) 3.6 (3.1–4.1) 6.2 (4.8–7.6)
3–79  2012–2013 2536 0.8 3.86 3.6 (3.2–4.0) 2.0 (1.8–2.2) 3.4 (3.0–3.8) 6.0 (5.1–7.0)
Monomethylarsonic acid (MMA) 3–79 2009–2011 2538 0.8 73.01 – <LOD <LOD 0.71f (<LOD–0.97)
3–79  2012–2013 2536 0.8 71.53 – <LOD <LOD <LODf (<LOD–0.89)
Cadmium 6–79 2007–2009 5491 0.09 9.71 0.34 (0.31–0.38) 0.16 (0.13–0.20) 0.37 (0.34–0.41) 0.67 (0.62–0.72)
3–79  2009–2011 6311 0.07 6.56 0.38 (0.34–0.43) 0.20 (0.16–0.25) 0.41 (0.35–0.47) 0.75 (0.66–0.84)
Cesium 3–79 2009–2011 6311 0.1 0.02 4.6 (4.3–4.9) 3.1 (2.8–3.4) 4.9 (4.6–5.3) 7.3 (6.7–7.9)
Cobalt  3–79 2009–2011 6304 0.06 6.87 0.23 (0.21–0.26) 0.088f (<LOD–0.12) 0.25 (0.21–0.29) 0.44 (0.40–0.49)
Copper  6–79 2007–2009 5492 0.3 0.29 9.0 (8.2–9.8) 5.6 (4.8–6.4) 9.9 (9.5–10) 15 (14–16)
3–79  2009–2011 6311 0.6 0.21 11 (10–11) 7.1 (6.6–7.7) 12 (11–13) 17 (17–18)
Fluoride  3–79 2009–2011 2530 20 0 500 (460–550) 300 (270–330) 480 (440–530) 850 (760–930)
3–79  2012–2013 2671 10 0 430 (390–480) 260 (220–300) 440 (390–490) 700 (590–810)
Lead  6–79 2007–2009 5492 0.1 7.54 0.48 (0.42–0.53) 0.28 (0.23–0.32) 0.52 (0.47–0.58) 0.91 (0.83–1.0)
3–79  2009–2011 6311 0.2 16.43 0.51 (0.49–0.54) 0.31 (0.29–0.33) 0.56 (0.53–0.60) 0.93 (0.87–1.0)
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Table 3 (Continued)
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
Manganese 6–79 2007–2009 5431 0.05 35.54 0.081 (0.072–0.092) <LOD 0.079 (0.067–0.091) 0.12 (0.087–0.15)
3–79  2009–2011 6309 0.2 70.41 – <LOD <LOD <LOD
Mercury  (inorganic) 3–79 2007–2009 5444 0.1 49.63 – <LOD 0.24 (0.19–0.29) 0.75 (0.65–0.85)
3–79  2012–2013 5696 0.2 50.42 – <LOD 0.19 (<LOD–0.24) 0.56 (0.48–0.65)
Molybdenum 6–79 2007–2009 5492 0.1 0 36 (33–40) 20 (17–23) 40 (37–43) 70 (66–74)
3–79  2009–2011 6311 1.0 0.02 45 (42–48) 27 (24–29) 49 (46–52) 83 (78–88)
Nickel  6–79 2007–2009 5491 0.2 3.15 1.1 (1.0–1.2) 0.65 (0.61–0.69) 1.1 (1.0–1.2) 2.0 (1.9–2.1)
3–79  2009–2011 6310 0.3 4.29 1.3 (1.2–1.4) 0.80 (0.75–0.85) 1.4 (1.3–1.5) 2.2 (2.1–2.4)
Selenium  6–79 2007–2009 5492 6 0.46 49 (45–53) 30 (26–34) 53 (48–58) 85 (79–91)
3–79 2009–2011 6311 4 0.14 52 (49–54) 34 (32–36) 59 (55–62) 83 (79–88)
Silver  3–79 2009–2011 6311 0.1 92.35 – <LOD <LOD <LOD
Thallium  3–79 2009–2011 6311 0.02 0.43 0.23 (0.21–0.24) 0.15 (0.13–0.16) 0.24 (0.22–0.27) 0.37 (0.34–0.40)
Tungsten  3–79 2009–2011 6310 0.2 65.63 – <LOD <LOD <LOD
Uranium  6–79 2007–2009 5491 0.01 87.05 – <LOD <LOD <LOD
3–79  2009–2011 6311 0.01 84.49 – <LOD <LOD <LOD
Vanadium  6–79 2007–2009 5492 0.1 90.37 – <LOD <LOD <LOD
3–79  2009–2011 6311 0.1 91.92 – <LOD <LOD <LOD
Zinc  6–79 2007–2009 5492 10 0.78 250 (240–270) 130 (120–150) 270 (250–280) 520 (490–550)
3–79  2009–2011 6311 10 0.41 320 (300–340) 190 (160–210) 350 (330–370) 600 (560–640)
Organophosphate insecticides and metabolites
Dimethylphosphate (DMP) 6–79 2007–2009 5467 0.8 20.27 2.9 (2.5–3.4) <LOD 3.0 (2.5–3.6) 7.3 (6.6–7.9)
3–79 2009–2011 2556 1 13.58 3.3 (2.9–3.7) 1.4 (1.1–1.7) 3.5 (3.0–4.0) 7.4 (6.6–8.2)
Dimethylthiophosphate (DMTP) 6–79 2007–2009 5474 0.6 30.76 2.0 (1.7–2.4) <LOD 2.0f (1.1–2.8) 6.9 (5.6–8.3)
3–79  2009–2011 2559 0.6 15.87 2.7 (2.3–3.2) 0.81 (<LOD–1.1) 2.8 (2.2–3.5) 8.1 (5.4–11)
Dimethyldithiophosphate (DMDTP) 6–79 2007–2009 5475 0.09 61.95 – <LOD <LOD 0.63 (0.42–0.85)
3–79  2009–2011 2537 0.3 49.11 – <LOD <LOD 0.87 (0.68–1.1)
Diethylphosphate (DEP) 6–79 2007–2009 5475 0.5 20.40 2.3 (2.0–2.6) <LODf (<LOD–1.0) 2.3 (2.0–2.6) 4.7 (4.4–5.0)
3–79  2009–2011 2556 1 13.58 2.8 (2.6–3.1) 1.3 (1.1–1.6) 2.8 (2.5–3.1) 5.7 (5.1–6.4)
Diethylthiophosphate (DETP) 6–79 2007–2009 5474 0.08 59.77 – <LOD <LOD 0.98 (0.82–1.1)
3–79  2009–2011 2511 0.3 23.26 0.66 (0.60–0.72) <LOD 0.60 (0.51–0.70) 1.2 (1.0–1.3)
Diethyldithiophosphate (DEDTP) 6–79 2007–2009 5475 0.06 96.84 – <LOD <LOD <LOD
3–79  2009–2011 2557 0.3 97.38 – <LOD <LOD <LOD
Phenoxy  herbicide
2,4-Dichlorophenoxyacetic acid (2,4-D) 6–79 2007–2009 5480 0.2 58.10 – <LOD <LOD 0.29 (0.21–0.36)
3–79  2009–2011 2551 0.2 41.98 – <LOD 0.22 (<LOD–0.26) 0.40 (0.35–0.45)
Phthalate metabolites
Mono-benzyl phthalate (MBzP) 6–49 2007–2009 3237 0.2 0 12 (9.7–14) 4.8 (3.8–5.8) 12 (9.4–14) 28 (23–33)
3–79  2009–2011 2559 0.05 0 7.5 (6.6–8.6) 3.4 (2.8–4.0) 7.1 (6.1–8.1) 16 (13–19)
Mono-n-butyl  phthalate (MnBP) 6–49 2007–2009 3237 0.2 0.03 23 (21–25) 11 (9.5–13) 23 (20–26) 46 (42–51)
3–79  2009–2011 2555 0.2 0 20 (18–22) 11 (8.7–12) 20 (18–22) 36 (33–39)
Mono-cyclohexyl phthalate (MCHP) 6–49 2007–2009 3237 0.2 87.24 – <LOD <LOD <LOD
3–79  2009–2011 2551 0.09 71.70 – <LOD <LOD NRg
Mono-ethyl phthalate (MEP) 6–49 2007–2009 3237 0.5 0.03 56 (47–66) 21 (18–23) 49 (40–57) 140 (110–170)
3–79  2009–2011 2561 0.3 0 44 (36–54) 18 (16–21) 42 (35–50) 100 (76–130)
3–79  2009–2011 2547 0.1 0.04 14 (12–16) 7.3 (6.1–8.5) 14 (12–16) 25 (20–30)
Mono-isononyl phthalate (MiNP) 6–49 2007–2009 3236 0.4 99.35 – <LOD <LOD <LOD
3–79 2009–2011 2556 0.3 99.30 – <LOD <LOD <LOD
Mono-methyl phthalate (MMP)  6–49 2007–2009 3237 5 73.40 – <LOD <LOD <LOD
3–79  2009–2011 2559 5 58.38 – <LOD <LOD <LOD
Mono-n-octyl  phthalate (MnOP) 6–49 2007–2009 3237 0.7 94.90 – <LOD <LOD <LOD
3–79  2009–2011 2558 0.3 98.51 – <LOD <LOD <LOD
Mono-3-carboxypropyl phthalate (MCPP) 6–49 2007–2009 3237 0.2 7.35 1.5 (1.3–1.6) 0.74 (0.63–0.86) 1.7 (1.4–1.9) 3.5 (3.2–3.9)
3–79  2009–2011 2543 0.06 1.22 1.9 (1.8–2.1) 1.0 (0.89–1.1) 2.0 (1.7–2.2) 3.8 (3.5–4.2)
Mono-2-ethylhexyl phthalate (MEHP) 6–49 2007–2009 3237 0.2 0.34 3.6 (3.2–4.0) 1.6 (1.4–1.8) 3.4 (2.9–4.0) 7.1 (6.2–7.9)
3–79  2009–2011 2498 0.08 0.60 1.9 (1.7–2.1) 0.97 (0.80–1.1) 1.9 (1.6–2.1) 3.4 (2.8–4.0)
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Table 3 (Continued)
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) 6–49 2007–2009 3237 0.2 0 14 (13–16) 6.8 (5.8–7.8) 13 (12–15) 28 (26–31)
3–79  2009–2011 2561 0.1 0 7.4 (6.9–8.0) 4.1 (3.7–4.5) 7.4 (6.7–8.1) 14 (12–15)
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 6–49 2007–2009 3237 0.4 0 23 (21–26) 11 (9.4–13) 23 (20–26) 47 (44–50)
3–79  2009–2011 2561 0.4 0.08 13 (12–14) 6.8 (6.1–7.4) 12 (12–13) 24 (22–25)
Polycyclic aromatic hydrocarbon metabolites
Benzo[a]pyrene
3-Hydroxybenzo[a]pyrene 3–79 2009–2011 2294 0.002 99.91 – <LOD <LOD <LOD
3–79  2012–2013 2378 0.003 99.96 – <LOD <LOD <LOD
Chrysene
2-Hydroxychrysene 3–79 2009–2011 2497 0.004 99.84 – <LOD <LOD <LOD
3–79  2012–2013 2496 0.005 99.96 – <LOD <LOD <LOD
3-Hydroxychrysene 3–79 2009–2011 2495 0.003 99.76 – <LOD <LOD <LOD
3–79  2012–2013 2498 0.003 99.92 – <LOD <LOD <LOD
4-Hydroxychrysene 3–79 2009–2011 2498 0.003 99.76 – <LOD <LOD <LOD
3–79  2012–2013 2498 0.002 99.84 – <LOD <LOD <LOD
6-Hydroxychrysene 3–79 2009–2011 2459 0.006 96.87 – <LOD <LOD <LOD
3–79  2012–2013 2494 0.002 99.84 – <LOD <LOD <LOD
Fluoranthene
3-Hydroxyﬂuoranthene 3–79 2009–2011 2265 0.008 98.23 – <LOD <LOD <LOD
3–79  2012–2013 2263 0.008 98.37 – <LOD <LOD <LOD
Fluorene
2-Hydroxyﬂuorene 3–79 2009–2011 2524 0.003 0 0.27 (0.24–0.29) 0.13 (0.11–0.14) 0.24 (0.21–0.27) 0.47 (0.38–0.57)
3–79  2012–2013 2514 0.006 0 0.26 (0.24–0.29) 0.11 (0.096–0.12) 0.22 (0.20–0.24) 0.57 (0.46–0.69)
3-Hydroxyﬂuorene 3–79 2009–2011 2523 0.001 0.04 0.096 (0.087–0.11) 0.042 (0.036–0.048) 0.081 (0.072–0.089) 0.18 (0.15–0.21)
3–79  2012–2013 2513 0.002 0 0.10 (0.090–0.11) 0.037 (0.032–0.042) 0.082 (0.072–0.091) 0.22f (0.14–0.30)
9-Hydroxyﬂuorene 3–79 2009–2011 2514 0.003 0 0.16 (0.15–0.17) 0.089 (0.079–0.099) 0.16 (0.14–0.17) 0.26 (0.22–0.29)
3–79  2012–2013 2499 0.004 0 0.15 (0.13–0.17) 0.081 (0.067–0.096) 0.14 (0.13–0.16) 0.28 (0.23–0.32)
Naphthalene
1-Hydroxynaphthalene 3–79 2009–2011 2522 0.1 0.79 1.5 (1.3–1.7) 0.59 (0.49–0.70) 1.3 (1.1–1.5) 2.9 (2.4–3.4)
3–79  2012–2013 2511 0.02 2.27 1.0 (0.89–1.2) 0.41 (0.37–0.46) 0.85 (0.68–1.0) 2.6 (2.1–3.1)
2-Hydroxynaphthalene 3–79 2009–2011 2503 0.05 0 3.8 (3.4–4.4) 1.7 (1.4–2.1) 3.8 (3.2–4.4) 8.9 (7.2–11)
3–79  2012–2013 2506 0.03 0 4.1 (3.6–4.6) 1.9 (1.6–2.3) 4.0 (3.4–4.6) 9.3 (7.7–11)
Phenanthrene
1-Hydroxyphenanthrene 3–79 2009–2011 2522 0.005 0.04 0.15 (0.14–0.17) 0.086 (0.077–0.096) 0.15 (0.14–0.17) 0.27 (0.23–0.30)
3–79  2012–2013 2505 0.002 0.04 0.15 (0.13–0.16) 0.079 (0.074–0.085) 0.13 (0.12–0.15) 0.28 (0.26–0.30)
2-Hydroxyphenanthrene 3–79 2009–2011 2520 0.003 0 0.067 (0.062–0.071) 0.042 (0.038–0.046) 0.065 (0.060–0.069) 0.099 (0.093–0.11)
3–79  2012–2013 2503 0.002 0 0.061 (0.054–0.068) 0.033 (0.029–0.037) 0.056 (0.048–0.064) 0.10 (0.092–0.11)
3-Hydroxyphenanthrene 3–79 2009–2011 2515 0.003 0 0.087 (0.080–0.095) 0.045 (0.038–0.052) 0.089 (0.080–0.098) 0.15 (0.13–0.17)
3–79  2012–2013 2505 0.002 0 0.083 (0.077–0.090) 0.043 (0.037–0.050) 0.081 (0.075–0.087) 0.16 (0.13–0.18)
4-Hydroxyphenanthrene 3–79 2009–2011 2519 0.001 0.08 0.024 (0.022–0.027) 0.0096 (0.0093–0.0099) 0.019 (0.016–0.022) 0.047 (0.039–0.054)
3–79  2012–2013 2495 0.003 4.33 0.021 (0.019–0.023) 0.010 (0.0087–0.011) 0.020 (0.016–0.023) 0.045 (0.038–0.052)
9-Hydroxyphenanthrene 3–79 2009–2011 2474 0.004 5.86 0.039 (0.034–0.044) 0.018 (0.016–0.021) 0.036 (0.029–0.043) 0.075 (0.058–0.092)
3–79  2012–2013 2295 0.004 3.66 0.036 (0.033–0.040) 0.016 (0.014–0.018) 0.034 (0.029–0.038) 0.072 (0.053–0.090)
Pyrene
1-Hydroxypyrene 3–79 2009–2011 2422 0.002 0.04 0.11 (0.099–0.12) 0.057 (0.050–0.064) 0.10 (0.092–0.11) 0.19 (0.17–0.22)
3–79  2012–2013 2410 0.003 0.04 0.088 (0.078–0.10) 0.044 (0.037–0.051) 0.087 (0.078–0.096) 0.17 (0.13–0.20)
Pyrethroid insecticide metabolites
4-Fluoro-3-phenoxybenzoic acid (4-F-3-PBA) 6–79 2007–2009 5224 0.008 56.45 – <LOD <LOD 0.014 (0.011–0.016)
3–79  2009–2011 2539 0.008 44.70 – <LOD 0.0091 (<LOD–0.010) 0.018 (0.013–0.023)
cis-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane-1-
carboxylic acid
(cis-DBCA)
6–79 2007–2009 5022 0.006 50.36 – <LOD <LOD 0.016 (0.013–0.019)
3–79  2009–2011 2535 0.006 37.24 0.012 (0.010–0.014) <LOD 0.0094 (0.0084–0.010) 0.030 (0.025–0.036)
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Table 3 (Continued)
Environmental Chemical Age Group (years) Year Sample Sizeb LOD %<LOD GMc (95% CI) P25 (95% CI) P50 (95% CI) P75 (95% CI)
cis-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane
carboxylic acid (cis-DCCA)
6–79 2007–2009 5431 0.007 1.57 0.085 (0.070–0.10) 0.035 (0.028–0.041) 0.071 (0.057–0.086) 0.17 (0.13–0.21)
3–79 2009–2011 2553 0.007 0.86 0.12 (0.10–0.15) 0.043 (0.036–0.050) 0.093 (0.076–0.11) 0.27f (0.17–0.37)
trans-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane
carboxylic acid (trans-DCCA)
6–79 2007–2009 5457 0.01 0.40 0.20 (0.17–0.24) 0.078 (0.066–0.090) 0.17 (0.14–0.20) 0.43 (0.33–0.53)
3–79  2009–2011 2558 0.01 0.35 0.29 (0.23–0.36) 0.097 (0.082–0.11) 0.22 (0.17–0.26) 0.67 (0.45–0.90)
3-Phenoxybenzoic acid (3-PBA) 6–79 2007–2009 5450 0.01 0.61 0.25 (0.21–0.31) 0.10 (0.083–0.12) 0.22 (0.17–0.27) 0.55 (0.42–0.68)
3–79 2009–2011 2516 0.01 0.04 0.43 (0.35–0.53) 0.15 (0.13–0.18) 0.36 (0.29–0.43) 0.94 (0.68–1.2)
Tobacco  biomarkers
Nicotine and metabolites
Anabasine (total) 12–79 2007–2009 2481 2.3 85.09 – <LOD <LOD <LOD
Anabasine  (free) 12–79 2012–2013 4168 1 86.2 – <LOD <LOD <LOD
Cotinine  (total) 12–79 2007–2009 2397 2 62.79 – <LOD <LOD NRg
Cotinine (free): All 6–79 2007–2009 5527 1 73.86 – <LOD <LOD NRg
3–79 2009–2011 6310 1 76.29 – <LOD <LOD NRg
3–79 2012–2013 5697 1 78.3 – <LOD <LOD NRg
Non-tobacco usersd 6–79 2007–2009 4662 1 87.56 – <LOD <LOD <LOD
3–79 2009–2011 5469 1 88.02 – <LOD <LOD <LOD
3–79  2012–2013 4967 1 89.81 – <LOD <LOD <LOD
Tobacco  userse 6–79 2007–2009 865 1 0 830 (710–890) 510 (380–630) 1000 (830–1200) 1600 (1500–1800)
3–79  2009–2011 841 1 0 880 (800–970) 570 (450–680) 1000 (910–1200) 1700 (1500–1900)
3–79 2012–2013 730 1 0 810 (670–990) 550 (420–680) 1000 (920–1100) 1500 (1300–1600)
Cotinine-n-glucuronide 12–79 2007–2009 2407 1 64.73 – <LOD <LOD NRg
12–79 2012–2013 4167 3.3 74.66 – <LOD <LOD NRg
Nicotine (total) 12–79 2007–2009 2309 1.8 72.15 – <LOD <LOD <LOD
Nicotine  (free) 12–79 2012–2013 4167 0.5 71.42 – <LOD <LOD NRg
Nicotine-n-glucuronide 12–79 2007–2009 2402 1.8 74.77 – <LOD <LOD <LOD
12–79  2012–2013 4168 0.5 71.52 – <LOD <LOD NRg
trans-3-Hydroxycotinine (total) 12–79 2007–2009 2126 2.7 66.09 – <LOD <LOD NRg
trans-3-Hydroxycotinine (free) 12–79 2012–2013 4167 1 62.73 – <LOD <LOD NRg
trans-3-Hydroxycotinine-glucuronide 12–79 2007–2009 2348 2.7 71.17 – <LOD <LOD <LOD
12–79  2012–2013 4168 50 81.38 – <LOD <LOD <LOD
Tobacco-speciﬁc nitrosamines (TSNA): 4-(Methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NNK) metabolites
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, free) 12–79 2007–2009 2481 1.3 65.94 – <LOD <LOD NRg
12–79 2012–2013 2214 1.4 59.21 – <LOD <LOD NRg
NNAL (total) 12–79 2007–2009 2481 1.3 56.35 – <LOD <LOD 11f (5.1–17)
12–79  2012–2013 2216 1.4 43.68 – <LOD <LOD NRg
Triazine herbicide metabolites
Atrazine mercapturate (AM) 3–79 2009–2011 2526 0.03 99.88 – <LOD <LOD <LOD
Diaminochlorotriazine (DACT) 3–79 2009–2011 2526 1 100 – <LOD <LOD <LOD
Desethylatrazine (DEA) 3–79 2009–2011 2526 0.2 100 – <LOD <LOD <LOD
Volatile  organic compounds and metabolites
S-Phenylmercapturic acid (S-PMA) 3–79 2009–2011 2525 0.08 22.10 0.20 (0.18–0.23) 0.090 (<LOD–0.11) 0.12 (0.095–0.15) 0.37 (0.27–0.47)
3–79  2012–2013 2472 0.08 34.67 0.17 (0.14–0.21) <LOD 0.10f (<LOD–0.16) 0.42f (0.25–0.60)
trans,trans-Muconic  acid (t,t-MA) 3–79 2009–2011 2523 0.8 0.20 64 (57–71) 29 (27–32) 59 (52–66) 130 (110–150)
3–79  2012–2013 2492 0.6 0 56 (47–67) 26 (21–31) 53 (41–65) 110 (82–140)
Phenol  3–79 2009–2011 2556 100 0.16 6600 (6200–7000) 3500 (3000–4000) 6600 (6100–7200) 12000 (10000–13000)
CI: conﬁdence interval; GM:  geometric mean; LOD: limit of detection; NR: not reported; P25: 25th percentile; P50: 50th percentile; P75: 75th percentile.
a Units for all chemicals are in g/L except for arsenic (As; speciated) which are expressed as g As/L.
b Sample sizes are the actual unweighted number of participants. GMs, percentiles and CIs are weighted estimates.
c GM was not calculated when the percentage of results <LOD was  greater than 40%.
d Respondents with urinary cotinine (free) concentrations ≤50 g/L were categorized as non-tobacco users.
e Respondents with urinary cotinine (free) concentrations >50 g/L were categorized as tobacco users.
f Coefﬁcient of variation is between 16.6% and 33.3%, use data with caution.
g Coefﬁcient of variation is greater than 33.3%, data are not reported.
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amples. Their GM concentrations over these two surveys ranged
rom 0.012 g/L for cis-DBCA to 0.43 g/L for 3-PBA. 4-F-3-PBA was
etected in less than 60% of samples. The phenoxy herbicide 2,4-
ichlorophenoxyacetic acid (2,4-D) was also detected in less than
0% of urine samples.
The chlorophenols 2,4,5-trichlorophenol (2,4,5-TCP), 2,4,6-
richlorophenol (2,4,6-TCP), and pentachlorophenol (PCP) were
ll detected in less than 7% of urine samples. The urinary 2,4-
ichlorophenol (2,4-DCP) GM concentrations were 0.94 g/L in
–79 year olds from CHMS cycle 1 and 1.2 g/L in 3–79 year olds
rom cycle 2. The dichlorophenol (2,5-DCP) GM concentration in
rine was 5.5 g/L in 3–79 year olds from cycle 2.
Polycyclic aromatic hydrocarbon metabolites were measured in
rine of 3–79 year olds in CHMS cycles 2 and 3. Urinary metabolites
or benzo[a]pyrene, chrysene, and ﬂuoranthene were all detected in
ess than 2% of samples. Conversely, metabolites for ﬂuorene, naph-
halene, phenanthrene, and pyrene were detected in 94% to 100%
f urine samples with GM concentrations ranging from 0.021 g/L
or 4-hydroxyphenanthrene to 4.1 g/L for 2-hydroxynaphthalene.
Eleven phthalate metabolites were measured in the urine of
–49 year olds in CHMS cycle 1 and 12 metabolites were mea-
ured in 3–79 year olds in cycle 2. The 6–49 year age range was
elected in cycle 1 to sample children and adults of child-bearing
ge. This was expanded to include phthalate metabolites measure-
ents across all ages in cycle 2. Low detection rates were observed
or mono-cyclohexyl phthalate (MCHP), mono-isononyl phthalate
MiNP), mono-methyl phthalate (MMP), and mono-n-octyl phtha-
ate (MnOP). Over the two surveys, GM concentrations for the other
ight metabolites ranged from 1.5 g/L for mono-3-carboxypropyl
hthalate (MCPP) to 56 g/L for mono-ethyl phthalate (MEP).
A total of 13 urinary tobacco biomarkers were measured
ver the ﬁrst three CHMS cycles. For the overall population
i.e. not partitioning by tobacco use status), the percentage of
amples of biomarkers that were <LOD ranged from 43.68%
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, total)) to
6.2% (anabasine, free). In this paper, only results for free coti-
ine were partitioned by tobacco use status, using the urinary free
otinine cutpoint of >50 g/L to identify tobacco users (Czoli and
ammond, 2015). Approximately 15% of respondents in each cycle
ere categorized as tobacco users. Over the three survey cycles,
etween 87.5% and 89.8% of non-tobacco users had free cotinine
oncentrations <LOD. On the other hand, GM concentrations for
ree cotinine in tobacco users were between 810 and 880 g/L.
. Discussion
Since the launch of the Canadian Health Measures Survey in
007, HBM results for three survey cycles (2007–2009, 2009–2011,
012–2013) have been released. At the time of this paper, cycle 4
2014–2015) collection has been completed and HBM data release
s expected in 2017. Field collection for cycle 5 (2016–2017) is in
rogress and planning for cycle 6 (2018–2019) is being ﬁnalized.
ore than 300 chemicals were nominated for CHMS biomonitor-
ng in the consultations carried out in 2003 and 2008. In order
o maximize the collection of HBM data for the nominated sub-
tances within the limitation of resources and burden on survey
articipants, the chemicals were apportioned across the survey
ycles. CHMS cycles 1–3 provide the ﬁrst nationally-representative
anadian HBM data based on individual blood and urine measure-
ents for 173 chemicals. Copper, lead and zinc were measured
n the nationally-representative 1978–1979 Canada Health SurveyPlease cite this article in press as: Haines, D.A., et al., An overview of hu
Health Measures Survey: 2007–2019. Int. J. Hyg. Environ. Health (201
Statistics Canada & Health and Welfare Canada, 1983). An addi-
ional 52 chemicals were measured exclusively in pooled serum
amples over these ﬁrst survey cycles with results for cycle 1 pub-
ished earlier (Rawn et al., 2014; Rawn et al., 2012). With up to PRESS
nd Environmental Health xxx (2016) xxx–xxx 13
279 chemicals being measured between 2007 and 2019, the CHMS
is fulﬁlling an important gap in human exposure monitoring in
Canada by providing nationally-representative HBM data for a wide
range of environmental chemicals.
The robust survey design and randomized nationally-
representative sampling strategy are important characteristics
that enable the CHMS to provide biomonitoring data for the overall
general Canadian population. In addition, the comprehensive
quality assurance and quality control protocols followed for all
aspects of the ﬁeldwork and laboratory analyses are key elements
to maximize the reliability and validity of the data and to reduce
systematic bias. The CHMS response rates of 74.9% (2007–2009),
73.9% (2009–2011) and 69.7% (2012–2013) for respondents
selected at the household level reporting to the MEC  for the
collection of physical measurements are similar to the 75.4%
(2007–2008), 77.3% (2009–2010) and 69.5% (2011–2012) reported
for the United States National Health and Nutrition Examination
Survey (NHANES) (CDC, 2015a) and the 62.3% response rate for
3–74 year olds in the 2006–2007 French National Nutrition and
Health Survey (Fréry et al., 2011).
In some instances, laboratory methods or analysis procedures
changed during a cycle or between cycles. In such cases, decisions
were made based on the nature of the laboratory issue and were
handled on a case by case basis to ensure quality and continuity
of results. For example, the inaccuracies in the standards used for
the analysis of urinary phthalate metabolites in cycle 1 and cycle
2 required the development of speciﬁc correction factors for each
phthalate metabolite in those cycles (Langlois et al., 2014). On  the
other hand, cases where substantial changes to the analytical meth-
ods were made, for example during the analysis of urinary BPA in
cycle 1, required the reanalysis of samples within the same cycle. In
cases where there was a change in laboratories between cycles, as
in the case of parabens between cycles 3 and 4, cross-over studies
were carried out to inform the need for sample re-analysis.
Trace elements such as copper, manganese, molybdenum, sele-
nium and zinc are essential nutrients required for the maintenance
of health (WHO, 1996) and their high detection rates in blood or
urine would be expected. On the other hand, many of the exoge-
nous chemicals presented in Tables 2 and 3 were detected in high
frequencies which suggest widespread exposure of Canadians to
these substances.
To illustrate HBM levels of selected chemicals, the CHMS cycle 3
is one of the few nationally- representative surveys internationally
that has measured acrylamide and its primary metabolite glyci-
damide via HbAA and HbGA. The greater than 99% detection of
these two  haemoglobin adducts indicates that most Canadians are
exposed to acrylamide. The CHMS GM concentrations are higher
than those reported in the 2003–2004 NHANES (CDC, 2009) for
both HbAA (73 vs 61.2 pmol/g Hb) and HbGA (68 vs 59.3 pmol/g
Hb). Comparisons should be made with prudence as there is a nine
year difference between the results of these two surveys. Smoking
is an important source of acrylamide exposure and food and other
factors may  contribute to exposure among non-smokers (Vesper
et al., 2010). The CHMS cycle 3 GM blood methylmercury con-
centration of 0.64 g Hg/L for 20–79 year olds is similar to the
value of 0.624 g/L reported for the United State population 20
years of age and older in 2011–2012 (CDC, 2015b). It also compares
to the CHMS total mercury concentrations in blood ranging from
0.82 g/L (20–39 year olds) to1.0 g/L (60–79 year olds) (Health
Canada, 2015). Other studies reported that organic/methylmercury
accounted for 62% (Cole et al., 2004) to 78% (Kim et al., 2012) of total
mercury in blood.man biomonitoring of environmental chemicals in the Canadian
6), http://dx.doi.org/10.1016/j.ijheh.2016.08.002
To our knowledge, the CHMS is the only HBM survey that
has collected urinary ﬂuoride measurements from a nationally-
representative sample and is reporting GM  concentrations of
500 g/L and 430 g/L for cycles 2 and 3 respectively in 3–79
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ear old Canadians. Mean values of urinary ﬂuoride concentra-
ions between 320 g/L and 4800 g/L have been reported in
argeted studies (Usuda et al., 2009). Fluoride compounds are ubiq-
itous in the environment, however, the major sources of exposure
o the general population are water, food, beverages, and den-
al products (Health Canada, 2010b). A panel of VOCs measured
n whole blood of 12–79 year olds has been included in CHMS
ycles 3–6. For CHMS cycle 3, low detection rates were observed
or trichloroethylene, tetrachloroethylene, and the four tri-
alomethanes (bromodichloromethane, dibromochloromethane,
ribromomethane and trichloromethane). Similar detection pat-
erns were observed in the United States population 12 years of
ge and older from the 2005–2006 NHANES. However, for the
rihalomethanes, the LODs in CHMS were higher compared to
005–2006 NHANES. Consequently, bromodichloromethane and
richloromethane were detected at frequencies >60% in NHANES
CDC, 2015b) and virtually not detected in the CHMS. Conversely,
oth surveys reported relatively high detection rates of benzene,
thylbenzene, toluene, and xylenes. The 50th percentile blood con-
entrations from the CHMS compared to those from the 2005–2006
HANES were 0.039 g/L vs 0.026 g/L for benzene, 0.025 vs
.035 g/L for ethylbenzene, 0.079 vs 0.120 g/L for toluene, 0.063
s 0.120 g/L for m- and p-xylene, and 0.022 vs 0.035 g/L for o-
ylene.
The CHMS is a nationally-representative survey and does not
arget speciﬁc sub-populations. To investigate speciﬁc popula-
ions other HBM surveys, cohort studies and regional programs
ave been implemented in Canada. These include the First Nations
iomonitoring Initiative that has focused on First Nations people
iving on reserves in southern Canada (AFN, 2013), the Maternal-
nfant Research on Environmental Chemicals studying pregnant
omen and their infants (Arbuckle et al., 2013), and HBM surveil-
ance in northern populations as part of the Northern Contaminants
rogram (Donaldson et al., 2010).
Although the CHMS is not a cause-effect study, associations
etween questionnaire-based information, physical measures,
ther health and nutrition biomarkers and environmental chem-
cals have been examined. For example, using CHMS cycle 1 data
or 20–79 year olds, after adjusting for potential confounders
uch as sex, alcohol drinking status, hypertension, urinary cre-
tinine and seafood consumption, Feseke et al. (2015) found
igniﬁcant positive associations between total urinary arsenic con-
entrations and the prevalence of Type 2 diabetes. Bushnik et al.
2014) observed a modest positive association between blood
ead concentrations and blood pressure measured in Canadians
ged 40–79 years in adjusted regression models using age, sex,
ducation, smoking, alcohol consumption, family history of high
lood pressure and antihypertensive medication use, physical
ctivity, body mass index, non-HDL cholesterol, and biomarker
ndicators of diabetes and chronic disease as covariates. Other
tudies based on CHMS data have observed positive associa-
ions between cholesterol outcomes and plasma perﬂuorohexane
ulfonate (PFHxS) concentrations (Fisher et al., 2013), and nega-
ive associations between lung function parameters and urinary
hthalate metabolites (Cakmak et al., 2014) and urinary dialkyl
hosphate metabolites concentrations (Ye et al., 2016).
An objective of HBM initiatives is to track time trends in popu-
ations. The data from the ﬁrst three CHMS cycles span a maximum
f four to six years (i.e. 2007–2009 to 2012–2013) with approx-
mately one half of measurements performed in more than one
ycle. Only cadmium, lead and total mercury in blood and BPA and
otinine in urine were measured in all three cycles. By selectingPlease cite this article in press as: Haines, D.A., et al., An overview of hu
Health Measures Survey: 2007–2019. Int. J. Hyg. Environ. Health (201
he chemicals in Tables 2 and 3 for which there is no overlap in
he 95% CI associated with the GM concentrations between CHMS
ycles, the following observations are made. In whole blood, the
M concentration for lead was 15% lower in cycle 3, and sele- PRESS
nd Environmental Health xxx (2016) xxx–xxx
nium, zinc and nickel were 5%, 8%, and 29% respectively lower
in CHMS cycle 2 than in cycle 1. The PFOS GM value in plasma
was 27% lower in cycle 2 than in cycle 1. In urine, GM concentra-
tions for copper, molybdenum, and zinc were 22%, 25%, and 28%
higher in cycle 2 compared to cycle 1. The GM for the phthalate
urinary metabolites monobenzyl phthalate (MBzP), monoethyl-
hexyl phthalate (MEHP), mono-(2-ethyl-5-oxohexyl) phthalate
(MEOHP) and mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP)
were between 38% and 47% lower whereas MCPP was  27% higher
in cycle 2 than in cycle 1. The GM value for the naphthalene urinary
metabolite 1-hydroxynaphthalene was 33% lower in cycle 3 than in
cycle 2 and the pyrethroid metabolite 3-phenoxybenzoic acid (3-
PBA) was  72% higher in cycle 2 than in cycle 1. These comparisons
are limited by differences in age groups as well as the relatively
short time frame of the CHMS since its inception. Temporal trends
may  become more apparent as HBM data from future CHMS surveys
become available.
CHMS biomonitoring data have been used in Canadian regula-
tory risk assessments of chemicals including perﬂuorooctanoic acid
(Environment Canada & Health Canada, 2012), decabromodiphenyl
ether (Health Canada, 2012), lead (Health Canada, 2013a),
cobalt (Environment Canada & Health Canada, 2014), phtha-
lates (Environment Canada & Health Canada, 2015b), selenium
(Environment Canada & Health Canada, 2015a) and deltamethrin
(PMRA, 2015).
CHMS cycles 4, 5 and 6 will continue to target sample sizes of
approximately 5700 following the survey sampling criteria and
protocols implemented in cycle 3. Measurements of metals and
trace elements in hair are being added as a new matrix in CHMS
cycles 5 (2016–2017) and 6 (2018–2019). Although beyond the
scope of this paper, indoor air measurements have been included in
CHMS cycles 2, 3, and 4 (Patry-Parisien et al., 2013; Wheeler et al.,
2013; Zhu et al., 2013) and tap water in cycles 3 and 4. The CHMS
collects blood and urine samples and also extracts DNA from con-
senting participants and stores these in a biobank for future health
studies (Statistics Canada, 2016).
National-level HBM surveys have also been conducted in other
countries such as Germany, Korea, France and the United States
(Kolossa-Gehring et al., 2012; Lee et al., 2012; Fréry et al., 2011;
CDC, 2009). HBM studies measure the internal dose of a given chem-
ical resulting from all routes of exposures. Hence, the HBM data
provide unambiguous evidence regarding chemical exposure and
are considered as a gold standard in exposure assessment (NRC,
2006). However, HBM data alone cannot inform health risk assess-
ment as risk is a function of both exposure and hazard. Different
approaches have been developed for the interpretation of HBM
data. These range from simple statistical tools such as reference
values (Schulz et al., 2011; Ewers et al., 1999) to complex tools such
as forward and reverse dosimetry involving a knowledge of physi-
ologically based pharmacokinetic modelling for interpreting HBM
data in a health risk context (Clewell et al., 2008; Hays et al., 2008).
Finally, for chemicals such as mercury, guidance values have been
developed that relate HBM data directly to health outcomes based
on epidemiological studies (NRC, 2006). For instance, methylmer-
cury blood guidance values for Canada and recommended public
health actions have been advanced with developmental neurotoxi-
city as the most sensitive outcome forming the basis for health risk
assessment and the derivation of HBM guidance values (Legrand
et al., 2010).
5. Conclusionsman biomonitoring of environmental chemicals in the Canadian
6), http://dx.doi.org/10.1016/j.ijheh.2016.08.002
The CHMS’s demonstrably robust planning, design and sam-
pling, and the comprehensive quality assurance and quality control
regime implemented for all aspect of the survey ensure high conﬁ-
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ence in the HBM results. Actions are taken continually to improve
eld and laboratory methods to increase the efﬁciency and qual-
ty of results. The HBM component of this survey, and the wide
ange of chemicals being measured fulﬁls an important knowledge
ap in Canadian population exposure monitoring and the resulting
ata are being used in regulatory risk assessment and public pol-
cy decisions to protect the health of Canadians. The biomonitoring
ontent for the CHMS has been established for the ﬁrst six cycles
f the survey and HBM results for 279 chemicals are expected by
019. Concurrent efforts are underway to develop concepts and
ools to help interpret HBM data and the population representative
haracteristic of the CHMS will feature strongly in the statistical
erivation of HBM reference values.
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